Succeed Holdings Limited Pharmaceutical Import Profile — Hong Kong (DGFT 2022–2026)

Name: Succeed Holdings Limited Pharmaceutical Import Records from India — 2 Products, $224.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Succeed Holdings Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $224.0K Trade | TransData Nexus

Succeed Holdings Limited

Pharmaceutical Importer · Hong Kong · Antimalarial & Antiparasitic Focus · $224.0K Total Trade · DGFT Verified

Succeed Holdings Limited is a pharmaceutical importer based in Hong Kong with a total trade value of $224.0K across 2 products in 2 therapeutic categories. Based on 10 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Succeed Holdings Limited sources from 6 verified Indian suppliers, with Shree Ssd Pharma Private Limited accounting for 48.8% of imports.

Succeed Holdings Limited — Import Portfolio & Supplier Network

Succeed Holdings Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Succeed Holdings Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Shree Ssd Pharma Private Limited	$1.2M	490	48.8%
Lloyd Laboratories Private Limited	$747.8K	24	31.5%
Ganpati Exim Inc

What Formulations Does Succeed Holdings Limited Import?

Formulation	Value	Ships
Dutavolve (dutasteride 0.5 MG soft	$145.4K	4
Pharmaceuticals products careprost eye	$84.7K	9
Dutavolve dutasteride 0.5 MG soft gelatin capsules batch ni- ac5001a (10x10s) (9948 packs)	$74.7K	2
Dutavolve dutasteride 0.5 MG soft gelatin capsules batch ni- ac5002a (10x10s) (9936 packs)	$74.6K	2
Dutavolve dutasteride 0.5 MG soft	$73.7K	2
Malefe mtf medroxyprogesterone acetate tablets USP 10MG (10x10s) (9840 packs)	$71.0K	2
Dutavolve - dutasteride 0.5MG soft gelatin capsules (3 x 10 s = 9732 packs)	$69.1K	2
Pharmaceutical product medicine : Pack of 4 TAB tadalafil tablets 20 MG	$65.9K	5
Pharmaceuticals products rybelsus 14 MG	$65.4K	3
Etinila ethinylestradiol tablets BP 0.05MG	$61.6K	4
Pharmaceutical products megalis 20MG tabstadalafil4	$58.0K	4
Pharmaceuticals article / ods / product / item rybelsus 7 MG	$52.8K	2
Pharmaceutical product medicine:Pack of 48 TAB ivermectin 12MG	$50.2K	2
Pharmaceutical product medicine : Pack of 48 TAB ivermectin 12MG	$50.0K	1
Pharmaceuticals products careprost	$49.4K	5

Succeed Holdings Limited imports 301 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ivermectin	Antimalarial & Antiparasitic	$124.0K	8	1.4%	8
2	Liraglutide	Diabetes & Endocrine	$100.0K	2	2.3%	3

Succeed Holdings Limited imports 2 pharmaceutical products across 2 categories into Hong Kong totaling $224.0K.

Succeed Holdings Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Succeed Holdings Limited is a Hong Kong-based pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company operates as a wholesaler, sourcing a diverse range of pharmaceutical products to meet the healthcare needs of the Hong Kong market. While specific details about its parent company are not publicly available, Succeed Holdings Limited plays a significant role in Hong Kong's pharmaceutical distribution network, ensuring the availability of essential medications to various healthcare providers and retailers.

2Distribution Network

Succeed Holdings Limited's distribution network encompasses multiple warehouse locations strategically situated across Hong Kong to facilitate efficient logistics and timely delivery of pharmaceutical products. The company's logistics capabilities are robust, enabling it to manage a diverse portfolio of products and cater to the dynamic demands of the Hong Kong healthcare sector. While the primary focus is on the Hong Kong market, the company's operations may extend to other regions, depending on specific business agreements and market opportunities.

3Industry Role

In Hong Kong's pharmaceutical supply chain, Succeed Holdings Limited functions primarily as a wholesaler. The company imports finished pharmaceutical formulations from various suppliers, including those in India, and distributes these products to local pharmacies, hospitals, and other healthcare facilities. This role is crucial in ensuring the steady supply of medications, contributing to the overall efficiency and effectiveness of the healthcare system in Hong Kong.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Succeed Holdings Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Succeed Holdings Limited's sourcing strategy reveals a significant concentration in its supplier base. The company imports finished pharmaceutical formulations from six unique Indian suppliers, with the top four accounting for approximately 95.7% of the total import value. This concentration indicates a strategic choice to establish strong, reliable partnerships with key suppliers, ensuring consistent product quality and supply. However, such dependency also poses potential risks, including supply chain disruptions due to geopolitical issues, regulatory changes, or operational challenges faced by these suppliers. The shipment data, which includes 10 total shipments, suggests a stable relationship with these suppliers, as evidenced by the consistent import volumes over the period.

2Supply Chain Resilience

The resilience of Succeed Holdings Limited's Indian supply chain is a critical factor in its operational stability. The company's reliance on a select group of suppliers may limit its ability to quickly adapt to changes in the supply chain, such as shifts in supplier capacity or market dynamics. The diversity of formulations imported, with 301 unique products, indicates a broad product range, which can mitigate risks associated with over-reliance on a single product line. However, the exposure to specific shipping routes and potential regulatory changes in both India and Hong Kong could impact the supply chain's resilience. Ensuring that key suppliers adhere to international Good Manufacturing Practice (GMP) standards is essential to maintain product quality and compliance with Hong Kong's regulatory requirements.

Importing Pharmaceuticals into Hong Kong — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Hong Kong

1Regulatory Authority & Framework

In Hong Kong, the Department of Health (DH) is the primary regulatory authority overseeing the safety, efficacy, and quality of all medicines marketed in the region. The DH enforces regulations under the Pharmacy and Poisons Ordinance (Cap. 138), which mandates that all pharmaceutical products be registered with the Pharmacy and Poisons Board of Hong Kong before they can be sold or distributed. This registration process ensures that products meet the required standards for public health and safety. Additionally, the Import and Export Ordinance (Cap. 60) governs the importation and exportation of pharmaceutical products, requiring importers to obtain appropriate licenses from the DH. (drugoffice.gov.hk)

2Import Licensing & GMP

Importers of pharmaceutical products in Hong Kong must obtain a Wholesale Dealer Licence (WDL) from the DH, which authorizes them to import and distribute pharmaceutical products. Each importation requires an Import Licence (Form 3) issued by the DH's Drug Evaluation and Import/Export Control Division. Regarding Good Manufacturing Practice (GMP), the DH requires that pharmaceutical manufacturers comply with international GMP standards, such as those set by the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This compliance ensures that imported products meet the necessary quality standards. (drugoffice.gov.hk)

Succeed Holdings Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Succeed Holdings Limited's focus on importing antimalarial and antiparasitic medications (55.4% of imports) and diabetes and endocrine treatments (44.6% of imports) aligns with the significant healthcare needs in Hong Kong. The prevalence of diseases such as malaria and diabetes in the region drives the demand for these therapeutic areas. By concentrating on these categories, the company addresses critical health concerns, ensuring the availability of essential treatments to the local population.

2Sourcing Profile

Succeed Holdings Limited's sourcing strategy emphasizes the importation of generic drugs, particularly in the antimalarial, antiparasitic, and diabetes treatment categories. The company imports a diverse range of formulations, with 301 unique products, indicating a preference for variety to meet different patient needs. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a suitable source for these products.

3Market Positioning

Based on its product mix, Succeed Holdings Limited serves multiple segments of the Hong Kong market, including retail pharmacies, hospitals, and government tenders. The company's focus on essential medications positions it as a key supplier in the wholesale distribution network, ensuring that critical treatments are accessible to various healthcare providers and institutions.

Seller's Guide — How to Become a Supplier to Succeed Holdings Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Succeed Holdings Limited's supply chain. The company's emphasis on quality and regulatory compliance presents an avenue for exporters who can meet these standards. Potential gaps in the current sourcing strategy, such as the need for additional product formulations or competitive pricing, could be addressed by new suppliers, enhancing the company's product offerings and market competitiveness.

2Requirements & Qualifications

Indian exporters seeking to supply Succeed Holdings Limited and the Hong Kong market must ensure that their products are registered with the Pharmacy and Poisons Board of Hong Kong. Compliance with international GMP standards, such as those recognized by PIC/S, is mandatory. Additionally, products must meet Hong Kong's labeling requirements, including bilingual labeling in Chinese and English, and adhere to serialization mandates for traceability.

3How to Approach

Frequently Asked Questions — Succeed Holdings Limited

What products does Succeed Holdings Limited import from India?

Succeed Holdings Limited imports 2 pharmaceutical products across 2 categories. Top imports: Ivermectin ($124.0K), Liraglutide ($100.0K).

Who supplies pharmaceuticals to Succeed Holdings Limited from India?

Succeed Holdings Limited sources from 6 verified Indian suppliers. The primary supplier is Shree Ssd Pharma Private Limited (48.8% of imports, $1.2M).

What is Succeed Holdings Limited's total pharmaceutical import value?

Succeed Holdings Limited's total pharmaceutical import value from India is $224.0K, based on 10 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Succeed Holdings Limited focus on?

Succeed Holdings Limited imports across 2 categories. The largest: Antimalarial & Antiparasitic (55.4%), Diabetes & Endocrine (44.6%).

Get Full Succeed Holdings Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.